A positive response to therapy in a paediatric patient with a renal rhabdoid tumour has enabled researchers to identify ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients with advanced clear cell ovarian and endometrial cancers who received ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Clear cell acanthoma or Degos' acanthoma is a distinct disease concerning its clinical, histopathological, and immunohistochemical features. Its pathologic nature - whether neoplastic or reactive - is ...

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to ...

The U.S. health secretary said people should have access to experimental therapies including unregulated uses of stem cells. But some methods have resulted in blindness, tumors and other injuries.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore ...

With clinical trials results trickling in, “antiaging” drugs that clear away senescent cells are proving to be promising — and confounding.

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

Once detached, the white blood cells engulf and consume the pathogens. This study was led by Wang, with Subhankar Kundu, a postdoctoral research fellow in his lab, serving as the first author.

Comparative survival outcomes of non-clear cell and clear cell renal cell carcinomas with indications for adjuvant pembrolizumab.. If you have the appropriate software installed, you can download ...

Background: The treatment landscape for non-clear cell renal cell carcinoma (nccRCC) lacks personalized therapeutic options. Although adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes ...